{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:39Z","timestamp":1787032899152,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"DOI":"10.7759\/cureus.85445","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T02:16:48Z","timestamp":1749176208000},"source":"Crossref","is-referenced-by-count":4,"title":["A Comprehensive Review of the Clinical Evidence on the Efficacy, Effectiveness, and Safety of Silodosin for the Treatment of Benign Prostatic Hyperplasia"],"prefix":"10.7759","author":[{"given":"Omar S","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komel A","family":"Bhojani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitany","family":"Bhargave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06628-8","article-title":"The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"7","author":"Lee SW","year":"2017","unstructured":"Lee SW, Chan EM, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017, 7:7984. 10.1038\/s41598-017-06628-8","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00213-6","article-title":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"3","year":"2022","unstructured":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019. a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022, 3:e754-76. 10.1016\/S2666-7568(22)00213-6","journal-title":"Lancet Healthy Longev"},{"key":"ref3","article-title":"Benign Prostatic Hyperplasia","author":"Ng M","year":"2024","unstructured":"Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare8020158","article-title":"Quality of life in older adults with benign prostatic hyperplasia","volume":"8","author":"Park S","year":"2020","unstructured":"Park S, Ryu JM, Lee M. Quality of life in older adults with benign prostatic hyperplasia. Healthcare (Basel). 2020, 8:158. 10.3390\/healthcare8020158","journal-title":"Healthcare (Basel)"},{"key":"ref5","unstructured":"European Association of Urology. Management of non-neurogenic male LUTS. (2024). Accessed. November 4, 2024: https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023","volume":"211","author":"Sandhu JS","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024, 211:11-9. 10.1097\/JU.0000000000003698","journal-title":"J Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_121_21","article-title":"The Urological Society of India guidelines on management of benign prostatic hyperplasia\/benign prostatic obstruction (executive summary)","volume":"37","author":"Sabnis RB","year":"2021","unstructured":"Sabnis RB, Mulawkar PM, Joshi RN. The Urological Society of India guidelines on management of benign prostatic hyperplasia\/benign prostatic obstruction (executive summary). Indian J Urol. 2021, 37:210-3. 10.4103\/iju.iju_121_21","journal-title":"Indian J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2017.924","article-title":"Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial","volume":"70","author":"Manohar CM","year":"2017","unstructured":"Manohar CM, Nagabhushana M, Karthikeyan VS, Sanjay RP, Kamath AJ, Keshavamurthy R. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. Cent European J Urol. 2017, 70:148-53. 10.5173\/ceju.2017.924","journal-title":"Cent European J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.714368","article-title":"Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"13","author":"Osman NI","year":"2012","unstructured":"Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012, 13:2085-96. 10.1517\/14656566.2012.714368","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","unstructured":"Central Statistics Office Ministry of Statistics and Programme Implementation Government of India. Elderly in India - profile and programmes. (2016). Accessed. November 4, 2024: https:\/\/www.mospi.gov.in\/sites\/default\/files\/publication_reports\/ElderlyinIndia_2016.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50608","article-title":"Association of benign prostatic hyperplasia with multimorbidity among older adults: insights from the Longitudinal Ageing Study in India (LASI), first wave","volume":"15","author":"Halder P Sr","year":"2023","unstructured":"Halder P Sr, Bhandari Y, Das A, Mamgai A. Association of benign prostatic hyperplasia with multimorbidity among older adults: insights from the Longitudinal Ageing Study in India (LASI), first wave. Cureus. 2023, 15:e50608. 10.7759\/cureus.50608","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-018-0326-7","article-title":"Silodosin 8\u00a0mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study","volume":"18","author":"Fusco F","year":"2018","unstructured":"Fusco F, Creta M, Longo N, Persico F, Franco M, Mirone V. Silodosin 8\u00a0mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study. BMC Urol. 2018, 18:12. 10.1186\/s12894-018-0326-7","journal-title":"BMC Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.07.008","article-title":"Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: a multicenter, prospective, open-label, single-arm, phase IV trial","volume":"121","author":"Cho KJ","year":"2018","unstructured":"Cho KJ, Lee JZ, Song YS, Choi JB, Kim DK, Kim YT, Kim JC. Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: a multicenter, prospective, open-label, single-arm, phase IV trial. Urology. 2018, 121:153-7. 10.1016\/j.urology.2018.07.008","journal-title":"Urology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13088","article-title":"Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: a European phase IV clinical study (SiRE study)","volume":"23","author":"Montorsi F","year":"2016","unstructured":"Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: a European phase IV clinical study (SiRE study). Int J Urol. 2016, 23:572-9. 10.1111\/iju.13088","journal-title":"Int J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.11.013","article-title":"Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study","volume":"83","author":"Choo MS","year":"2014","unstructured":"Choo MS, Song M, Kim JH, et al.. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study. Urology. 2014, 83:875-81. 10.1016\/j.urology.2013.11.013","journal-title":"Urology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12906","article-title":"Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data","volume":"115","author":"Novara G","year":"2015","unstructured":"Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. BJU Int. 2015, 115:802-14. 10.1111\/bju.12906","journal-title":"BJU Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-013-1228-7","article-title":"Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies","volume":"32","author":"Eisenhardt A","year":"2014","unstructured":"Eisenhardt A, Schneider T, Cruz F, Oelke M. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014, 32:1119-25. 10.1007\/s00345-013-1228-7","journal-title":"World J Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12289","article-title":"Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"12","author":"Matsumoto S","year":"2020","unstructured":"Matsumoto S, Kasamo S, Hashizume K. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Low Urin Tract Symptoms. 2020, 12:86-91. 10.1111\/luts.12289","journal-title":"Low Urin Tract Symptoms"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.144912","article-title":"Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial","volume":"46","author":"Pande S","year":"2014","unstructured":"Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial. Indian J Pharmacol. 2014, 46:601-7. 10.4103\/0253-7613.144912","journal-title":"Indian J Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.178825","article-title":"A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia","volume":"48","author":"Manjunatha R","year":"2016","unstructured":"Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016, 48:134-40. 10.4103\/0253-7613.178825","journal-title":"Indian J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.02.068","article-title":"Reasons for prescription change of \u03b11-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"84","author":"Kim TN","year":"2014","unstructured":"Kim TN, Nam JK, Lee KS, et al.. Reasons for prescription change of \u03b11-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2014, 84:427-32. 10.1016\/j.urology.2014.02.068","journal-title":"Urology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.08.111","article-title":"Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study)","volume":"197","author":"Matsukawa Y","year":"2017","unstructured":"Matsukawa Y, Funahashi Y, Takai S, et al.. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study). J Urol. 2017, 197:452-8. 10.1016\/j.juro.2016.08.111","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000502661","article-title":"What are factors contributing to improvement of overactive bladder symptoms after alpha-1 blocker treatment in patients with both storage and voiding symptoms?","volume":"103","author":"Matsukawa Y","year":"2019","unstructured":"Matsukawa Y, Majima T, Takai S, Funahashi Y, Kato M, Gotoh M. What are factors contributing to improvement of overactive bladder symptoms after alpha-1 blocker treatment in patients with both storage and voiding symptoms?. Urol Int. 2019, 103:439-43. 10.1159\/000502661","journal-title":"Urol Int"},{"key":"ref24","article-title":"Role of silodosin in patients with LUTS\/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study","volume":"21","author":"Masciovecchio S","year":"2017","unstructured":"Masciovecchio S, Di Pasquale AB, Ranieri G, Romano G, Di Clemente L. Role of silodosin in patients with LUTS\/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study. Eur Rev Med Pharmacol Sci. 2017, 21:4941-5.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1519-2","article-title":"Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH","volume":"33","author":"Osman NI","year":"2015","unstructured":"Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015, 33:697-706. 10.1007\/s00345-015-1519-2","journal-title":"World J Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0258-4","article-title":"Post-marketing surveillance of silodosin in patients with benign prostatic hyperplasia and poor response to existing alpha-1 blockers: the SPLASH study","volume":"19","author":"Takahashi H","year":"2019","unstructured":"Takahashi H, Kubono S, Taneyama T, Kuramoto K, Mizutani H, Tanaka N, Yoshida M. Post-marketing surveillance of silodosin in patients with benign prostatic hyperplasia and poor response to existing alpha-1 blockers: the SPLASH study. Drugs R D. 2019, 19:47-55. 10.1007\/s40268-018-0258-4","journal-title":"Drugs R D"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13757","article-title":"Silodosin as second-line \u03b1-blocker monotherapy in patients with benign prostatic hyperplasia: a prospective observational study","volume":"25","author":"Ichihara K","year":"2018","unstructured":"Ichihara K, Masumori N, Iwasawa A, et al.. Silodosin as second-line \u03b1-blocker monotherapy in patients with benign prostatic hyperplasia: a prospective observational study. Int J Urol. 2018, 25:849-54. 10.1111\/iju.13757","journal-title":"Int J Urol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04071-7","article-title":"Prospective comparison of tadalafil 5\u00a0mg alone, silodosin 8\u00a0mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"40","author":"AbdelRazek M","year":"2022","unstructured":"AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5\u00a0mg alone, silodosin 8\u00a0mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022, 40:2063-70. 10.1007\/s00345-022-04071-7","journal-title":"World J Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12177","article-title":"Comparison of silodosin versus tadalafil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"9","author":"Yoshida M","year":"2017","unstructured":"Yoshida M, Origasa H, Seki N. Comparison of silodosin versus tadalafil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Low Urin Tract Symptoms. 2017, 9:176-86. 10.1111\/luts.12177","journal-title":"Low Urin Tract Symptoms"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2017.1.31","article-title":"Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation","volume":"89","author":"Cakiroglu B","year":"2017","unstructured":"Cakiroglu B, Hazar AI, Sinanoglu O, Arda E, Ekici S. Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation. Arch Ital Urol Androl. 2017, 89:31-3. 10.4081\/aiua.2017.1.31","journal-title":"Arch Ital Urol Androl"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/03915603231215936","article-title":"Does the duration of catheterization have an impact on the outcome of trial without catheter in patients with acute urine retention (AUR) due to benign prostatic hyperplasia (BPH)? A prospective randomized study","volume":"91","author":"Abuelnaga M","year":"2024","unstructured":"Abuelnaga M, Elawady H, Mahmoud MA, Mostafa D, Samir M. Does the duration of catheterization have an impact on the outcome of trial without catheter in patients with acute urine retention (AUR) due to benign prostatic hyperplasia (BPH)? A prospective randomized study. Urologia. 2024, 91:107-11. 10.1177\/03915603231215936","journal-title":"Urologia"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23935","article-title":"Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies","volume":"38","author":"Matsukawa Y","year":"2019","unstructured":"Matsukawa Y, Takai S, Majima T, et al.. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn. 2019, 38:941-9. 10.1002\/nau.23935","journal-title":"Neurourol Urodyn"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.05.031","article-title":"Effects of withdrawing \u03b11-blocker from combination therapy with \u03b11-blocker and 5\u03b1-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics","volume":"198","author":"Matsukawa Y","year":"2017","unstructured":"Matsukawa Y, Takai S, Funahashi Y, Majima T, Kato M, Yamamoto T, Gotoh M. Effects of withdrawing \u03b11-blocker from combination therapy with \u03b11-blocker and 5\u03b1-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics. J Urol. 2017, 198:905-12. 10.1016\/j.juro.2017.05.031","journal-title":"J Urol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4975851","article-title":"Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study","volume":"2016","author":"Hagiwara K","year":"2016","unstructured":"Hagiwara K, Koie T, Iwamura H, et al.. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. Biomed Res Int. 2016, 2016:4975851. 10.1155\/2016\/4975851","journal-title":"Biomed Res Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00059814","article-title":"Ageing and the epidemiology of multimorbidity","volume":"44","author":"Divo MJ","year":"2014","unstructured":"Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014, 44:1055-68. 10.1183\/09031936.00059814","journal-title":"Eur Respir J"},{"key":"ref36","article-title":"Long QT Syndrome","author":"Al-Akchar M","year":"2022","unstructured":"Al-Akchar M, Siddique MS. Long QT Syndrome. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0344-z","article-title":"Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia","volume":"75","author":"Keating GM","year":"2015","unstructured":"Keating GM. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs. 2015, 75:207-17. 10.1007\/s40265-014-0344-z","journal-title":"Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12915","article-title":"Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what are the factors for continuation or withdrawal?","volume":"22","author":"Yamanishi T","year":"2015","unstructured":"Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what are the factors for continuation or withdrawal?. Int J Urol. 2015, 22:1143-8. 10.1111\/iju.12915","journal-title":"Int J Urol"},{"key":"ref39","unstructured":"Food and Drug Administration. RAPAFLO\u00ae (silodosin). Highlights of prescribing information. (2024). Accessed. November 4, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022206s012lbl.pdf."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941130","article-title":"Risk of intraoperative floppy iris syndrome among selective alpha-1 blockers-A consistency model of 6,488 cases","volume":"9","author":"Wang YH","year":"2022","unstructured":"Wang YH, Huang LC, Tsai SH, Chen YJ, Wu CL, Kang YN. Risk of intraoperative floppy iris syndrome among selective alpha-1 blockers-A consistency model of 6,488 cases. Front Med (Lausanne). 2022, 9:941130. 10.3389\/fmed.2022.941130","journal-title":"Front Med (Lausanne)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2020.02.023","article-title":"Changing aspects of male sexual functions accompanying treatment of benign prostatic hyperplasia with silodosin 8\u00a0mg per day","volume":"17","author":"Cihan A","year":"2020","unstructured":"Cihan A, Kazaz \u0130O, Y\u0131ld\u0131r\u0131m \u00d6, et al.. Changing aspects of male sexual functions accompanying treatment of benign prostatic hyperplasia with silodosin 8\u00a0mg per day. J Sex Med. 2020, 17:1094-100. 10.1016\/j.jsxm.2020.02.023","journal-title":"J Sex Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-12-29","article-title":"Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia","volume":"12","author":"Sakata K","year":"2012","unstructured":"Sakata K, Morita T. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia. BMC Urol. 2012, 12:29. 10.1186\/1471-2490-12-29","journal-title":"BMC Urol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12095","article-title":"Effects of silodosin on sexual function - realistic picture from the everyday clinical practice","volume":"3","author":"Capogrosso P","year":"2015","unstructured":"Capogrosso P, Serino A, Ventimiglia E, et al.. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice. Andrology. 2015, 3:1076-81. 10.1111\/andr.12095","journal-title":"Andrology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2147\/rru.s5004","article-title":"Management of benign prostatic hyperplasia with silodosin","volume":"1","author":"Yamanishi T","year":"2009","unstructured":"Yamanishi T, Mizuno T, Kamai T, Yoshida K, Sakakibara R, Uchiyama T. Management of benign prostatic hyperplasia with silodosin. Open Access J Urol. 2009, 1:1-7. 10.2147\/rru.s5004","journal-title":"Open Access J Urol"},{"key":"ref45","unstructured":"World Health Organization. Cardiovascular diseases. (2024). Accessed. November 4, 2024: https:\/\/www.who.int\/india\/health-topics\/cardiovascular-diseases."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100156","article-title":"The burgeoning cardiovascular disease epidemic in Indians - perspectives on contextual factors and potential solutions","volume":"12","author":"Kalra A","year":"2023","unstructured":"Kalra A, Jose AP, Prabhakaran P, et al.. The burgeoning cardiovascular disease epidemic in Indians - perspectives on contextual factors and potential solutions. Lancet Reg Health Southeast Asia. 2023, 12:100156. 10.1016\/j.lansea.2023.100156","journal-title":"Lancet Reg Health Southeast Asia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358878-a-comprehensive-review-of-the-clinical-evidence-on-the-efficacy-effectiveness-and-safety-of-silodosin-for-the-treatment-of-benign-prostatic-hyperplasia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T02:16:50Z","timestamp":1749176210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358878-a-comprehensive-review-of-the-clinical-evidence-on-the-efficacy-effectiveness-and-safety-of-silodosin-for-the-treatment-of-benign-prostatic-hyperplasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.85445","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}